Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SON-1010 + atezolizumab in platinum-resistant ovarian cancer
NCT05756907Phase 2Terminated
- Sponsor
- Sonnet BioTherapeutics
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 2, open-label trial of SON-1010 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (8 arms), sponsored by Sonnet BioTherapeutics. Primary endpoints: Safety and Tolerability of SON-1010 in Combination with Atezolizumab at 1 year and Maximum Tolerated Dose at 1 year. Started Sep 2023; status: terminated.
02
Drugs
SON-1010
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT05756907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05756907.